Influence of host immunoregulatory genes, ER stress and gut microbiota on the shared pathogenesis of inflammatory bowel disease and Type 1 diabetes

Immunotherapy

Volumn 5, Issue 12, 2013, Pages 1357-1366

  Gjymishka, Altin ^a   Coman, Roxana M ^a   Brusko, Todd M ^a   Glover, Sarah C ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

autoimmune diseases; Crohns disease; host genetics; IL 18RAP; SNP; Type 1 diabetes mellitus

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA A24 ANTIGEN; HLA DRB1 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 18 RECEPTOR ALPHA; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 27; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; LEUCINE RICH REPEAT KINASE 2; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; X BOX BINDING PROTEIN 1;

ADAPTIVE IMMUNITY; ALLELE; ANTIGEN PRESENTATION; AUTOIMMUNITY; AUTOPHAGY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELIAC DISEASE; CHROMOSOME 6P; CLOSTRIDIUM DIFFICILE INFECTION; CROHN DISEASE; CROSS REACTION; DENDRITIC CELL; DNA POLYMORPHISM; DNA SEQUENCE; ENDOPLASMIC RETICULUM STRESS; ENTERITIS; ENTEROVIRUS INFECTION; ENVIRONMENTAL FACTOR; GENE INTERACTION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HEREDITY; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE FLORA; MACROPHAGE; META ANALYSIS (TOPIC); NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; ULCERATIVE COLITIS;

ANIMALS; DIABETES MELLITUS, TYPE 1; DIGESTIVE SYSTEM; ENDOPLASMIC RETICULUM STRESS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY; INFLAMMATORY BOWEL DISEASES; MICROBIOTA; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84889585999     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.130     Document Type: Review

References (115)

1. Das KM, Biancone L. Is IBD an autoimmune disorder? Inflamm. Bowel Dis. 14(Suppl. 2), S97-S101 (2008)
2. Broberger O, Perlmann P. Autoantibodies in human ulcerative colitis. J. Exp. Med. 110, 657-674 (1959)
3. Brandtzaeg P. Autoimmunity and ulcerative colitis: can two enigmas make sense together? Gastroenterology 109, 307-312 (1995)
4. Fiocchi C, Roche JK, Michener WM. High prevalence of antibodies to intestinal epithelial antigens in patients with inflammatory bowel disease and their relatives. Ann. Intern. Med. 110, 786-794 (1989) (Pubitemid 19128996)
5. Brant SR. Promises, delivery, and challenges of inflammatory bowel disease risk gene discovery. Clin. Gastroenterol. Hepatol. 11, 22-26 (2013)
6. Dahlquist G. The aetiology of Type 1 diabetes: an epidemiological perspective. Acta Paediatrica 425, 5-10 (1998) (Pubitemid 28478142)
7. Tattersall RB, Pyke DA. Diabetes in identical twins. Lancet 2, 1120-1125 (1972)
8. Kaprio J, Tuomilehto J, Koskenvuo M et al. Concordance for Type 1 (insulin-dependent) and Type 2 (non-insulin-dependent) diabetes mellitus in a population-based cohort of twins in Finland. Diabetologia 35, 1060-1067 (1992)
9. Cho JH, Brant SR. Recent insights into the genetics of inflammatory bowel disease. Gastroenterology 140, 1704-1712 (2011)
10. Todd JA. D'oh! Genes and environment cause Crohn's disease. Cell 141, 1114-1116 (2010)
11. Giongo A, Gano KA, Crabb DB et al. Toward defining the autoimmune microbiome for Type 1 diabetes. ISME J. 5, 82-91 (2011)
12. Nokoff N, Rewers M. Pathogenesis of Type 1 diabetes: lessons from natural history studies of high-risk individuals. Ann. NY Acad. Sci. 1281, 1-15 (2013)
13. Lees CW, Barrett JC, Parkes M, Satsangi J. New IBD genetics: common pathways with other diseases. Gut 60, 1739-1753 (2011)
14. Van Limbergen J, Wilson DC, Satsangi J. The genetics of Crohn's disease. Ann. Rev. Genom. Hum. Genet. 10, 89-116 (2009)
15. Grant SF, Hakonarson H. Genome-wide association studies in Type 1 diabetes. Curr. Diabetes Reports 9, 157-163 (2009)
16. Abecasis GR, Altshuler D, Auton A et al. A map of human genome variation from population-scale sequencing. Nature 467, 1061-1073 (2010)
17. Morey M, Fernandez-Marmiesse A, Castineiras D et al. A glimpse into past, present, and future DNA sequencing. Mol. Genet. Metab. 110, 3-24 (2013)
18. Pettersson E, Lundeberg J, Ahmadian A. Generations of sequencing technologies. Genomics 93, 105-111 (2009)
19. Silverberg MS, Mirea L, Bull SB et al. A population-and family-based study of canadian families reveals association of HLA DRB10103 with colonic involvement in inflammatory bowel disease. Inflamm. Bowel Dis. 9, 1-9 (2003) (Pubitemid 36124242)
20. Thompson AI, Lees CW. Genetics of ulcerative colitis. Inflamm. Bowel Dis. 17, 831-848 (2011)
21. Lappalainen M, Halme L, Turunen U et al. Association of IL23R, TNFRSF1A, and HLA-DRB1 0103 allele variants with inflammatory bowel disease phenotypes in the Finnish population. Inflamm. Bowel Dis. 14, 1118-1124 (2008)
22. Fernando MM, Stevens CR, Walsh EC et al. Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genet. 4, e1000024 (2008)
23. Newman B, Silverberg MS, Gu X et al. Card15 and HLA DRB1 alleles influence susceptibility and disease localization in Crohn's disease. Am. J. Gastroenterol. 99, 306-315 (2004) (Pubitemid 38279874)
24. Aly TA, Ide A, Humphrey K et al. Genetic prediction of autoimmunity: initial oligogenic prediction of anti-islet autoimmunity amongst DR3/DR4-DQ8 relatives of patients with Type 1a diabetes. J. Autoimmunity 25(Suppl.), 40-45 (2005) (Pubitemid 41728043)
25. Noble JA, Valdes AM, Varney MD et al. HLA class I and genetic susceptibility to Type 1 diabetes: results from the Type 1 diabetes genetics consortium. Diabetes 59, 2972-2979 (2010)
26. Nejentsev S, Howson JM, Walker NM et al. Localization of Type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature 450, 887-892 (2007) (Pubitemid 350231332)
27. Wang K, Baldassano R, Zhang H et al. Comparative genetic analysis of inflammatory bowel disease and Type 1 diabetes implicates multiple loci with opposite effects. Hum. Mol. Genet. 19, 2059-2067 (2010)
28. Franke A, McGovern DP, Barrett JC et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat. Genet. 42, 1118-1125 (2010)
29. Wang MH, Fiocchi C, Ripke S et al. A novel approach to detect cumulative genetic effects and genetic interactions in Crohn's disease. Inflamm. Bowel Dis. 19(9), 1799-1808 (2013)
30. Doecke JD, Simms LA, Zhao ZZ et al. Genetic susceptibility in IBD: overlap between ulcerative colitis and Crohn's disease. Inflamm. Bowel Dis. 19, 240-245 (2013)
31. Hugot JP, Chamaillard M, Zouali H et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411, 599-603 (2001) (Pubitemid 32531408)
32. Cadwell K, Liu JY, Brown SL et al. A key role for autophagy and the autophagy gene ATG16L1 in mouse and human intestinal Paneth cells. Nature 456, 259-263 (2008)
33. Parkes M, Barrett JC, Prescott NJ et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat. Genet. 39, 830-832 (2007) (Pubitemid 47014496)
34. Barrett JC, Hansoul S, Nicolae DL et al. Genome-wide association defmore than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 40, 955-962 (2008)
35. Concannon P, Rich SS, Nepom GT. Genetics of Type 1a diabetes. N. Engl. J. Med. 360, 1646-1654 (2009)
36. Smyth DJ, Cooper JD, Bailey R et al. A genome-wide association study of nonsynonymous snps identifies a Type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. Nat. Genet. 38, 617-619 (2006) (Pubitemid 43927300)
37. Huang J, Ellinghaus D, Franke A, Howie B, Li Y. 1000 Genomes-based imputation identifies novel and refined associations for the Wellcome trust case-control consortium Phase 1 data. Eur. J. Hum. Genet. 20, 801-805 (2012)
38. Bradfield JP, Qu HQ, Wang K et al. A genome-wide meta-analysis of six Type 1 diabetes cohorts identifies multiple associated loci. PLoS Genet. 7, e1002293 (2011)
39. Jostins L, Ripke S, Weersma RK et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119-124 (2012)
40. Onengut-Gumuscu S, Concannon P. The genetics of Type 1 diabetes: lessons learned and future challenges. J. Autoimmunity 25(Suppl.), 34-39 (2005) (Pubitemid 41728042)
41. Claesson MH, Nicoletti F, Stosic-Grujicic S, Doria A, Zampieri S. Interactions between infections and immune-inflammatory cells in Type 1 diabetes mellitus and inflammatory bowel diseases: evidences from animal models. Clin. Exper. Rheumatol. 26, S8-S11 (2008) (Pubitemid 351578090)
42. Bottini N, Musumeci L, Alonso A et al. A functional variant of lymphoid tyrosine phosphatase is associated with Type I diabetes. Nat. Genet. 36, 337-338 (2004) (Pubitemid 38437254)
43. Barrett JC, Clayton DG, Concannon P et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of Type 1 diabetes. Nat. Genet. 41, 703-707 (2009)
44. Andersen V, Ernst A, Christensen J et al. The polymorphism rs3024505 proximal to IL-10 is associated with risk of ulcerative colitis and Crohns disease in a Danish case-control study. BMC Med. Genet. 11, 82 (2010)
45. Glocker EO, Kotlarz D, Boztug K et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N. Engl. J. Med. 361, 2033-2045 (2009)
46. Glocker EO, Kotlarz D, Klein C, Shah N, Grimbacher B. IL-10 and IL-10 receptor defects in humans. Ann. NY Acad. Sci. 1246, 102-107 (2011)
47. Kotlarz D, Beier R, Murugan D et al. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology 143, 347-355 (2012)
48. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10- deficient mice develop chronic enterocolitis. Cell 75, 263-274 (1993) (Pubitemid 23320290)
49. Hagenbaugh A, Sharma S, Dubinett SM et al. Altered immune responses in interleukin 10 transgenic mice. J. Exper. Med. 185, 2101-2110 (1997) (Pubitemid 27265994)
50. Glocker EO, Frede N, Perro M et al. Infant colitis -it's in the genes. Lancet 376, 1272 (2010)
51. Zhernakova A, van Diemen CC, Wijmenga C. Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat. Rev. Genet. 10, 43-55 (2009)
52. Smyth DJ, Plagnol V, Walker NM et al. Shared and distinct genetic variants in Type 1 diabetes and celiac disease. N. Engl. J. Med. 359, 2767-2777 (2008)
53. Hunt KA, Zhernakova A, Turner G et al. Newly identified genetic risk variants for celiac disease related to the immune response. Nat. Genet. 40, 395-402 (2008) (Pubitemid 351450876)
54. Muzes G, Molnar B, Tulassay Z, Sipos F. Changes of the cytokine profile in inflammatory bowel diseases. World J. Gastroenterol. 18, 5848-5861 (2012)
55. Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol. Rev. 223, 20-38 (2008) (Pubitemid 351986169)
56. Grunnet LG, Mandrup-Poulsen T. Cytokines and Type 1 diabetes: a numbers game. Diabetes 60, 697-699 (2011)
57. Nepom GT, Ehlers M, Mandrup-Poulsen T. Anti-cytokine therapies in T1D: concepts and strategies. Clin. Immunol. doi:10.1016/j. clim.2013.02.003 (2013) (Epub ahead of print)
58. Thomas HE, Graham KL, Chee J et al. Proinflammatory cytokines contribute to development and function of regulatory T cells in Type 1 diabetes. Ann. NY Acad. Sci. 1283, 81-86 (2013)
59. Hanifi-Moghaddam P, Schloot NC, Kappler S, Seissler J, Kolb H. An association of autoantibody status and serum cytokine levels in Type 1 diabetes. Diabetes 52, 1137-1142 (2003) (Pubitemid 36523347)
60. Pizarro TT, Michie MH, Bentz M et al. IL18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J. Immunol. 162, 6829-6835 (1999) (Pubitemid 29309411)
61. Furuya D, Yagihashi A, Komatsu M et al. Serum interleukin-18 concentrations in patients with inflammatory bowel disease. J. Immunother. 25(Suppl. 1), S65-S67 (2002) (Pubitemid 34260760)
62. Elinav E, Strowig T, Kau AL et al. Nlrp6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 145, 745-757 (2011)
63. Dinarello CA. Interleukin-18 and the pathogenesis of inflammatory diseases. Semin. Nephrol. 27, 98-114 (2007)
64. Schenk M, Mueller C. Adaptations of intestinal macrophages to an antigen-rich environment. Semin. Immunol. 19, 84-93 (2007) (Pubitemid 46810284)
65. Hisamatsu T, Kanai T, Mikami Y et al. Immune aspects of the pathogenesis of inflammatory bowel disease. Pharmacol. Ther. 137, 283-297 (2013)
66. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8, 958-969 (2008)
67. Mantovani A, Sica A, Sozzani S et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25, 677-686 (2004) (Pubitemid 39457982)
68. Watanabe N, Ikuta K, Okazaki K et al. Elimination of local macrophages in intestine prevents chronic colitis in interleukin-10-deficient mice. Dig. Dis. Sci. 48, 408-414 (2003) (Pubitemid 36233012)
69. Sakuraba A, Sato T, Kamada N et al. Th1/Th17 immune response is induced by mesenteric lymph node dendritic cells in Crohn's disease. Gastroenterology 137, 1736-1745 (2009)
70. van Belle TL, Coppieters KT, von Herrath MG. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol. Rev. 91, 79-118 (2011)
71. Jun HS, Santamaria P, Lim HW, Zhang ML, Yoon JW. Absolute requirement of macrophages for the development and activation of beta-cell cytotoxic CD8+ T-cells in T-cell receptor transgenic NOD mice. Diabetes 48, 34-42 (1999) (Pubitemid 29019350)
72. Han S, Donelan W, Reeves W, Yang L-J. Autoantigen-specific immunotherapy. In: Type 1 Diabetes -Pathogenesis, Genetics and Immunotherapy. Wagner D (Ed.) InTech, Rijeka, Croatia (2011)
73. Orr MT, Lanier LL. Natural killer cell education and tolerance. Cell 142, 847-856 (2010)
74. Takayama T, Kamada N, Chinen H et al. Imbalance of NKP44(+)NKP46(-) and NKP44(-)NKP46(+) natural killer cells in the intestinal mucosa of patients with Crohn's disease. Gastroenterology 139, 882-892, 892. e881-e883 (2010)
75. Steel AW, Mela CM, Lindsay JO, Gazzard BG, Goodier MR. Increased proportion of CD16(+) nk cells in the colonic lamina propria of inflammatory bowel disease patients, but not after azathioprine treatment. Aliment. Pharmacol. Ther. 33, 115-126 (2011)
76. Ginsburg CH, Dambrauskas JT, Ault KA, Falchuk ZM. Impaired natural killer cell activity in patients with inflammatory bowel disease: evidence for a qualitative defect. Gastroenterology 85, 846-851 (1983) (Pubitemid 13000636)
77. Dotta F, Censini S, van Halteren AG et al. Coxsackie b4 virus infection of beta cells and natural killer cell insulitis in recent-onset Type 1 diabetic patients. Proc. Natl Acad. Sci. USA 104, 5115-5120 (2007) (Pubitemid 47186185)
78. Brauner H, Elemans M, Lemos S et al. Distinct phenotype and function of NK cells in the pancreas of nonobese diabetic mice. J. Immunol. 184, 2272-2280 (2010)
79. Feuerer M, Shen Y, Littman DR, Benoist C, Mathis D. How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic islets. Immunity 31, 654-664 (2009)
80. Brusko TM, Putnam AL, Bluestone JA. Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol. Rev. 223, 371-390 (2008) (Pubitemid 351986182)
81. Kornete M, Mason ES, Piccirillo CA. Immune regulation in T1D and T2D: prospective role of FoxP3+ Treg cells in disease pathogenesis and treatment. Front. Endocrinol. 4, 76 (2013)
82. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Ann. Rev. Immunol. 30, 531-564 (2012)
83. Boden EK, Snapper SB. Regulatory T cells in inflammatory bowel disease. Curr. Opin. Gastroenterol. 24, 733-741 (2008)
84. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation. J. Exper. Med. 192, 295-302 (2000) (Pubitemid 30470312)
85. Ghiringhelli F, Ménard C, Martin F, Zitvogel L. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol. Rev. 214, 229-238 (2006) (Pubitemid 44707914)
86. Kerdiles Y, Ugolini S, Vivier E. T cell regulation of natural killer cells. J. Exper. Med. 210, 1065-1068 (2013)
87. Rutkowski DT, Hegde RS. Regulation of basal cellular physiology by the homeostatic unfolded protein response. J. Cell Biol. 189, 783-794 (2010)
88. Kaser A, Martinez-Naves E, Blumberg RS. Endoplasmic reticulum stress: implications for inflammatory bowel disease pathogenesis. Curr. Opin. Gastroenterol. 26, 318-326 (2010)
89. Kaser A, Lee AH, Franke A et al. XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell 134, 743-756 (2008)
90. Harding HP, Zeng H, Zhang Y et al. Diabetes mellitus and exocrine pancreatic dysfunction in Perk-/-mice reveals a role for translational control in secretory cell survival. Mol. Cell 7, 1153-1163 (2001) (Pubitemid 32607350)
91. Delepine M, Nicolino M, Barrett T et al. EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome. Nat. Genet. 25, 406-409 (2000) (Pubitemid 32983431)
92. Wolcott CD, Rallison ML. Infancy-onset diabetes mellitus and multiple epiphyseal dysplasia. J. Pediatrics 80, 292-297 (1972)
93. Thornton CM, Carson DJ, Stewart FJ. Autopsy findings in the Wolcott-Rallison syndrome. Pediatr. Pathol. Lab. Med. 17, 487-496 (1997) (Pubitemid 27237485)
94. Dave M, Higgins PD, Middha S, Rioux KP. The human gut microbiome: current knowledge, challenges, and future directions. Transl. Med. 160, 246-257 (2012)
95. Kleessen B, Kroesen AJ, Buhr HJ, Blaut M. Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls. Scand. J. Gastroenterol. 37, 1034-1041 (2002)
96. Lucke K, Miehlke S, Jacobs E, Schuppler M. Prevalence of Bacteroides and Prevotella spp. in ulcerative colitis. J. Med. Microbiol. 55, 617-624 (2006)
97. D'Haens GR, Geboes K, Peeters M et al. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 114, 262-267 (1998) (Pubitemid 28093532)
98. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology 134, 577-594 (2008) (Pubitemid 351173057)
99. Frank DN, St Amand AL, Feldman RA et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc. Natl Acad. Sci. USA 104, 13780-13785 (2007) (Pubitemid 350003397)
100. Manichanh C, Borruel N, Casellas F, Guarner F. The gut microbiota in IBD. Nat. Rev. Gastroenterol. Hepatol. 9, 599-608 (2012)
101. Manichanh C, Rigottier-Gois L, Bonnaud E et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 55, 205-211 (2006) (Pubitemid 43117279)
102. Ott SJ, Musfeldt M, Wenderoth DF et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 53, 685-693 (2004) (Pubitemid 38561447)
103. Wen L, Ley RE, Volchkov PY et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 455, 1109-1113 (2008)
104. Aroniadis OC, Brandt LJ. Fecal microbiota transplantation: past, present and future. Curr. Opin. Gastroenterol. 29, 79-84 (2013)
105. Borody TJ, Warren EF, Leis SM et al. Bacteriotherapy using fecal flora: toying with human motions. J. Clin. Gastroenterol. 38, 475-483 (2004) (Pubitemid 38808419)
106. Oikarinen M, Tauriainen S, Oikarinen S et al. Type 1 diabetes is associated with enterovirus infection in gut mucosa. Diabetes 61, 687-691 (2012)
107. Vaarala O. Is the origin of Type 1 diabetes in the gut? Immunol. Cell Biol. 90, 271-276 (2012)
108. Bason C, Lorini R, Lunardi C et al. In Type 1 diabetes a subset of anti-Coxsackievirus b4 antibodies recognize autoantigens and induce apoptosis of pancreatic beta cells. PLoS ONE 8, e57729 (2013)
109. Serreze DV, Wasserfall C, Ottendorfer EW et al. Diabetes acceleration or prevention by a Coxsackievirus b4 infection: critical requirements for both interleukin-4 and gamma interferon. J. Virol. 79, 1045-1052 (2005) (Pubitemid 40053888)
110. Cinek O, Tapia G, Witso E et al. Enterovirus rna in peripheral blood may be associated with the variants of rs1990760, a common Type 1 diabetes associated polymorphism in IFIH1. PLoS ONE 7, e48409 (2012)
111. Coppieters KT, Wiberg A, Tracy SM, von Herrath MG. Immunology in the clinic review series: focus on Type 1 diabetes and viruses: the role of viruses in Type 1 diabetes: a difficult dilemma. Clin. Exper. Immunol. 168, 5-11 (2012)
112. Khan RR, Lawson AD, Minnich LL et al. Gastrointestinal norovirus infection associated with exacerbation of inflammatory bowel disease. J. Pediatric Gastroenterol. Nutr. 48, 328-333 (2009)
113. Christen U, Bender C, von Herrath MG. Infection as a cause of Type 1 diabetes? Curr. Opin. Rheumatol. 24, 417-423 (2012)
114. Hara N, Alkanani AK, Ir D et al. The role of the intestinal microbiota in Type 1 diabetes. Clin. Immunol. 146, 112-119 (2013)
115. Knosel T, Schewe C, Petersen N, Dietel M, Petersen I. Prevalence of infectious pathogens in Crohn's disease. Pathol. Res. Prac. 205, 223-230 (2009)